Pharma 4.0 Market Report 2025: Projected Growth and Technological Advancements The “Pharma 4.0 – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering, providing an extensive analysis of the…
Merck’s SC Pembrolizumab Shows Noninferior PK to IV KEYTRUDA in Trial Merck, known as MSD outside of the United States and Canada, has presented the first data from the pivotal…
Novotech Report Highlights Surge in siRNA Research with 150+ Clinical Trials (2020-2024) Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its latest preclinical…
Equillium Announces Q4 & Full-Year 2024 Results, Corporate & Clinical Updates Equillium, Inc., a clinical-stage biotechnology company specializing in immunobiology, has reported its financial results for the fourth quarter and…
Kardigan Acquires Prolaio to Build Innovative Heart Health Platform Kardigan, a heart health company focused on modernizing cardiovascular (CV) drug development, has announced its acquisition of Prolaio, a clinical intelligence…
Havah Therapeutics Files Patent for HAV-088 in Breast Cancer Treatment Havah Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for the prevention and treatment of breast cancer, has…
Japan Approves TIVDAK® for Advanced Cervical Cancer Treatment Genmab A/S has announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved TIVDAK® (tisotumab vedotin) for the treatment…
Blue Lake Biotechnology’s Intranasal COVID-19 Vaccine Candidate Demonstrates Long-Lasting Immunity and Broad Protection Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company specializing in intranasal vaccine development, along with its affiliate…
Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural history of knee…
Alcon Acquires Majority Stake in Aurion Biotech to Advance Corneal Cell Therapy Alcon, a global leader in eye care, has announced the acquisition of a majority interest in Aurion Biotech,…
Savara Secures Up to $200 Million in Non-Dilutive Debt Financing from Hercules Capital Savara Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare respiratory diseases, has announced…
FDA Approves CABOMETYX® (Cabozantinib) for Advanced Neuroendocrine Tumors, Expanding Treatment Options Exelixis, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment…